Cover ImageSALE
市場調查報告書

人類呼吸道融合病毒(RSV)治療藥的全球市場:2016-2020年

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 409502
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
人類呼吸道融合病毒(RSV)治療藥的全球市場:2016-2020年 Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
出版日期: 2016年12月09日 內容資訊: 英文 74 Pages
簡介

全球人類呼吸道融合病毒(RSV)治療藥的市場,預計從2016年到2020年以4.27%的年複合成長率擴大。

本報告提供全球人類呼吸道融合病毒(RSV)治療藥的市場調查,市場概要,主要的產品範例,疾病概要,開發平台趨勢,市場環境,各藥物分類的趨勢,各地區的收益規模的變化與預測,市場成長的各種影響因素分析,競爭環境,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的提供產品

第3章 市場調查手法

第4章 簡介

第5章 疾病概要

  • 關於疾病
  • 症狀
  • 原因
  • 風險要素
  • 併發症
  • 檢驗、診斷
  • 主要的購買標準

第6章 開發平台分析

第7章 市場環境

  • 全球呼吸道融合病毒(RSV)治療藥市場
  • 波特的五力分析

第8章 市場分析:各藥物類別

  • 認證核可藥
  • 非標籤藥物藥

第9章 地區分析

  • 美國
  • 歐洲
  • 其他地區

第10章 市場推動因素

  • 大規模的患者群的存在加速市場成長
  • 新產品投入市場
  • 新的診斷工具擴大患者人口

第11章 推動因素的影響

第12章 市場課題

  • 由於醫療機關的指南的連續變更對市場成長的影響
  • 市場循環的性質成為市場機會的障礙
  • 市場上的藥物的特定的可用性引導低的普及率

第13章 推動因素、課題的影響

第14章 市場趨勢

  • 新的進入經營者的市場動態的變化可能性
  • 於策略性聯盟造成的革新強化
  • 新興經濟圈對R&D的積極參加

第15章 供應商環境

  • 競爭模式

第16章 主要供應商分析

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
  • 其他有力供應商

第17章 附錄

第18章 關於Technavio

目錄
Product Code: IRTNTR11070

About Human Respiratory Syncytial Virus Drugs

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Technavio's analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The market is divided into the following segments based on geography:

  • Europe
  • ROW
  • US

Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical

Other Prominent Vendors

  • Ablynx
  • ADMA Biologics
  • Alnylam Pharmaceuticals
  • Ark Biosciences
  • Aviragen Therapeutics
  • Bavarian Nordic
  • Boehringer Ingelheim
  • Gilead Sciences
  • ImmunoVaccine Technologies
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Medivir
  • Mucosis
  • Mymetics Corporation
  • Novavax
  • Regeneron Pharmaceuticals
  • ReViral
  • Vaxart

Market driver

  • Novel diagnostic tools increase patient population.
  • For a full, detailed list, view our report

Market challenge

  • Continuous change in guidelines from healthcare organizations impacts market growth.
  • For a full, detailed list, view our report

Market trend

  • Emergence of new entrants likely to change market dynamics.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Symptoms
  • Causes
  • Risk factors
  • Complications
  • Tests and diagnosis
  • Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global respiratory syncytial virus drugs market
  • Five forces analysis

PART 08: Market segmentation by category of drug

  • Approved Drugs
  • Off-label drugs

PART 09: Geographical segmentation

  • Human respiratory syncytial virus drugs market in US
  • Human respiratory syncytial virus drugs market in Europe
  • Human respiratory syncytial virus drugs market in ROW

PART 10: Market drivers

  • Presence of large patient pool fuels market growth
  • Launch of novel products
  • Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges

  • Continuous change in guidelines from healthcare organizations impacts market growth
  • Cyclical nature of market hinders growth opportunities
  • Limited drugs in market leading to low penetration rates

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of new entrants likely to change market dynamics
  • Growing strategic collaborations fostering innovation
  • Active participation from emerging economies toward R&D

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market
  • Exhibit 03: Snapshot of RSV infection
  • Exhibit 04: Key buying criteria for RSV drugs
  • Exhibit 05: Factors affecting the adoption rates of RSV drugs
  • Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
  • Exhibit 07: Percentage share of drug candidates by stage of development
  • Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market
  • Exhibit 09: Global human respiratory syncytial virus drugs market snapshot
  • Exhibit 10: Analysis of global human respiratory syncytial drugs market
  • Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
  • Exhibit 12: Emerging vendors and their initiatives
  • Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market
  • Exhibit 14: Opportunity analysis in developed and emerging markets
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
  • Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
  • Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
  • Exhibit 19: Incidence of RSV infections in US (on average every year)
  • Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
  • Exhibit 21: Key drivers and challenges in US
  • Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
  • Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe
  • Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
  • Exhibit 25: Key drivers and challenges in ROW
  • Exhibit 26: Trends in RSV epidemics
  • Exhibit 27: Potential products
  • Exhibit 28: Impact of drivers
  • Exhibit 29: Change in guidelines of AAPCID and its consequences
  • Exhibit 30: Impact of cyclical nature of RSV epidemics
  • Exhibit 31: Factors affecting penetration rates
  • Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Potential entrants
  • Exhibit 35: Strategic alliances
  • Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
  • Exhibit 37: Market share analysis 2015
  • Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
  • Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market
  • Exhibit 40: AstraZeneca: Key highlights
  • Exhibit 41: AstraZeneca: Strength assessment
  • Exhibit 42: AstraZeneca: Strategy assessment
  • Exhibit 43: AstraZeneca: Opportunity assessment
  • Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
  • Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015
  • Exhibit 46: AbbVie: Strength assessment
  • Exhibit 47: AbbVie: Strategy assessment
  • Exhibit 48: AbbVie: Opportunity assessment
  • Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions)
  • Exhibit 50: GSK: Profile
  • Exhibit 51: GSK: Strength assessment
  • Exhibit 52: GSK: Strategy assessment
  • Exhibit 53: GSK: Opportunity assessment
  • Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions)
  • Exhibit 55: GSK: Geographical segmentation of Ventolin 2015
  • Exhibit 56: Teva Pharmaceutical: Profile
  • Exhibit 57: Teva Pharmaceutical: Strength assessment
  • Exhibit 58: Teva Pharmaceutical strategy assessment
  • Exhibit 59: Teva Pharmaceutical: Opportunity assessment
  • Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
Back to Top